WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/131909    International Application No.:    PCT/US2009/040943
Publication Date: 29.10.2009 International Filing Date: 17.04.2009
A61K 38/00 (2006.01), G01N 33/53 (2006.01)
Applicants: BIO-RAD LABORATORIES, INC. [US/US]; 1000 Alfred Nobel Drive Hercules, CA 94547 (US) (For All Designated States Except US).
WATKINS, Michael, I. [US/US]; (US) (For US Only).
MARR, Gregory, A. [US/US]; (US) (For US Only).
YANG, Xiaoyun [CN/US]; (US) (For US Only).
BRUEHL, Richard [US/US]; (US) (For US Only).
SHAN, Daming [US/US]; (US) (For US Only).
COLEMAN, Patrick, F. [US/US]; (US) (For US Only)
Inventors: WATKINS, Michael, I.; (US).
MARR, Gregory, A.; (US).
YANG, Xiaoyun; (US).
BRUEHL, Richard; (US).
SHAN, Daming; (US).
COLEMAN, Patrick, F.; (US)
Agent: TRIMBLE, Alexander, R.; (US)
Priority Data:
61/046,693 21.04.2008 US
Abstract: front page image
(EN)The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing on the solid support the gliadin fusion protein via the tag. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.
(FR)La présente invention concerne un procédé permettant de déterminer si un sujet souffre de maladie cœliaque en mettant en contact un échantillon de fluide corporel prélevé sur le sujet et un antigène constitué d’une protéine de fusion de gliadine immobilisée sur un support solide. La protéine de fusion de gliadine de l’antigène contient une gliadine recombinante déamidée liée à un marqueur tel que la protéine glutathione-S transférase (GST). L’antigène est préparé par immobilisation de la protéine de fusion de gliadine sur le support solide par l’intermédiaire du marqueur. L’antigène peut en outre inclure un tissu transglutaminase (tTG) réticulé avec la protéine de fusion de gliadine. Lorsqu’un tTG est présent, ledit tTG et la gliadine recombinante déamidée sont mélangés avant l’immobilisation en phase solide.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)